retatrutide nonalcoholic fatty liver disease trial nash A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis retatrutide nonalcoholic fatty liver disease

BMC Pregnancy and Childbirth, 24, 720

Type 2 Diabetes The efficacy and safety of SYMLIN were evaluated in 2 (a 26-week and a 52-week) randomized, double-blind, placebo-controlled trials in patients with type 2 diabetes

In addition to the aforementioned adverse reactions, GLP-1RA was also shown to increase the risk of triggering pancreatitis and adverse thyroid events

Study results so far indicate that retatrutide is more effective than any existing weight management medication and may be almost as effective as bariatric surgery

In clinical comparisons, tirzepatide maximum dose (15 mg) produces approximately 20-22% weight loss